Registered in London since September 2015, Orchard Therapeutics (Europe) Limited is a private limited company with Companies House number 09759506. Its registered address is 245 Hammersmith Road, W6 8PW. The company's core activity, as indicated by SIC code 72110, is research and experimental development on biotechnology. The company is a licensed Skilled Worker sponsor, holding a Worker (A rating). This means it has been vetted by the Home Office and is approved to recruit overseas staff. Such a designation often accompanies a genuine need for specialized personnel, which is plausible for a biotechnology research firm. The A rating reflects compliance with sponsorship record-keeping duties. The name and address suggest this is the European arm of a wider therapeutic development organization. Although the specific product focus is not disclosed in the available facts, companies in this sector typically engage in scientific research, assay development, and translational medicine. In the case of Orchard Therapeutics, general industry knowledge points to gene therapy for rare diseases, but this is an inference and should be verified separately. The London office likely hosts research teams, and possibly administrative and regulatory functions, though such details are not confirmed. Public records give no indication of employee count or international reach. Based on the typical scale of similar biotechnology subsidiaries, the team could range from tens to hundreds of people, but this is speculative. An international presence is likely given the 'Europe' designation, but no concrete evidence supports this.

Registered in London since September 2015, Orchard Therapeutics (Europe) Limited is a private limited company with Companies House number 09759506. Its registered address is 245 Hammersmith Road, W6 8PW. The company's core activity, as indicated by SIC code 72110, is research and experimental development on biotechnology. The company is a licensed Skilled Worker sponsor, holding a Worker (A rating). This means it has been vetted by the Home Office and is approved to recruit overseas staff. Such a designation often accompanies a genuine need for specialized personnel, which is plausible for a biotechnology research firm. The A rating reflects compliance with sponsorship record-keeping duties. The name and address suggest this is the European arm of a wider therapeutic development organization. Although the specific product focus is not disclosed in the available facts, companies in this sector typically engage in scientific research, assay development, and translational medicine. In the case of Orchard Therapeutics, general industry knowledge points to gene therapy for rare diseases, but this is an inference and should be verified separately. The London office likely hosts research teams, and possibly administrative and regulatory functions, though such details are not confirmed. Public records give no indication of employee count or international reach. Based on the typical scale of similar biotechnology subsidiaries, the team could range from tens to hundreds of people, but this is speculative. An international presence is likely given the 'Europe' designation, but no concrete evidence supports this.